White blood cell count measured prior to cancer development is associated with future risk of venous thromboembolism--the Tromsø study.
BACKGROUND: Elevated white blood cell (WBC) count is associated with risk of venous thromboembolism (VTE) in cancer patients initiating chemotherapy. It is not known whether the risk of VTE by WBC count in cancer patients is causal or merely a consequence of the malignant disease. To address this qu...
Main Authors: | Kristine Blix, Hilde Jensvoll, Sigrid K Brækkan, John-Bjarne Hansen |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3762748?pdf=render |
Similar Items
-
Platelet count measured prior to cancer development is a risk factor for future symptomatic venous thromboembolism: the Tromsø Study.
by: Hilde Jensvoll, et al.
Published: (2014-01-01) -
Weight Change and Risk of Venous Thromboembolism: The Tromsø Study.
by: Lars Daae Horvei, et al.
Published: (2016-01-01) -
Impact of respiratory symptoms and oxygen saturation on the risk of incident venous thromboembolism—the Tromsø study
by: Trond Børvik, et al.
Published: (2020-02-01) -
Atrial fibrillation, venous thromboembolism, ischemic stroke, and all‐cause mortality: The Tromsø study
by: Erin Mathiesen Hald, et al.
Published: (2020-08-01) -
Impact of Venous Thromboembolism on the Formation and Progression of Carotid Atherosclerosis: The Tromsø Study
by: Caroline Lind, et al.
Published: (2017-06-01)